Arkolith/Insider Trading/ACRS/Form 4

Molineaux Christopher P.

DirectorAclaris Therapeutics, Inc. (ACRS) · full profile →Form 4 · filed Jun 8, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
1 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 5, 2026Option exercise(M)12K——70K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 5, 2026Option exercise(M)12K—$00
Jun 4, 2026Grant(A)42K—$042K
Jun 4, 2026Grant(A)11K—$011K

Transaction Codes

M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001654773-26-000003) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML